XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2
RESTRUCTURING
 6 Months Ended
Jun. 30, 2024
Restructuring Charges [Abstract]  
RESTRUCTURING RESTRUCTURING
2023 Restructuring Plan

In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities. Consistent with our prioritization and efficiency goals communicated earlier this year, BMS continues to execute on strategic productivity initiatives through portfolio prioritization and management of our operating costs. Total expected restructuring costs under the 2023 Restructuring Plan to be incurred through 2026 are approximately $1.5 billion. These costs consist primarily of employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.
Celgene and Other Acquisition Plans

Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). The remaining charges of approximately $400 million consist primarily of employee termination costs, IT system integration costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.

The following provides the charges related to restructuring initiatives by type of cost:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in millions2024202320242023
2023 Restructuring Plan$264 $170 $332 $231 
Celgene and Other Acquisition Plans93 64 337 138 
Total charges$357 $234 $669 $369 
Employee termination costs$260 $109 $477 $174 
Other termination costs— 4 3 6 
Provision for restructuring260 113 480 180 
Integration expenses74 59 145 126 
Accelerated depreciation20 12 34 13 
Asset impairments— 50 2 50 
Other shutdown costs3 — 8 — 
Total charges$357 $234 $669 $369 
Cost of products sold$3 $36 $17 $37 
Marketing, selling and administrative6 20 12 20 
Research and development14 6 15 6 
Other (income)/expense, net334 172 625 306 
Total charges$357 $234 $669 $369 

The following summarizes the charges and spending related to restructuring plan activities:
Six Months Ended June 30,
Dollars in millions20242023
Beginning balance $188 $47 
Provision for restructuring480 180 
Foreign currency translation and other(3)1 
Payments(234)(48)
Ending balance$431 $180